CGON - NASDAQ
CG Oncology, Inc. Common stock
$54.42
-0.85%CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
At a Glance
Live Snapshotcgon
Research Development Expenses
Last Annual Value
116.64M
3-Year CAGR
59%
5-Year CAGR
45%
10-Year CAGR
20%
CG Oncology, Inc. Common stock Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
CG Oncology, Inc. Common stock NASDAQ:CGON | 116.64M | 36.6% | 44.8% | N/A | |
 Travere Therapeutics, Inc. NASDAQ:TVTX | 206.01M | -5.6% | 0.5% | 11.3% | |
 Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | 750.00M | 5.0% | 8.6% | 15.1% | |
 Apogee Therapeutics, Inc. NASDAQ:APGE | 214.71M | 46.4% | N/A | N/A | |
 Tarsus Pharmaceuticals, Inc. NASDAQ:TARS | 64.32M | 8.5% | 9.0% | N/A | |
 Disc Medicine, Inc. NASDAQ:IRON | 170.64M | 35.1% | 46.6% | N/A | |
 Celcuity Inc. NASDAQ:CELC | 145.00M | 33.8% | 41.3% | 47.1% | |
 Legend Biotech Corporation NASDAQ:LEGN | 415.80M | 2.8% | 5.8% | N/A |
CG Oncology, Inc. Common stock Fair Value Envelope
Related Guides
Continue your CGON research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.